Idoroenyi Amanam to Hematopoietic Stem Cell Transplantation
This is a "connection" page, showing publications Idoroenyi Amanam has written about Hematopoietic Stem Cell Transplantation.
Connection Strength
4.392
-
Chronic GVHD: review advances in prevention, novel endpoints, and targeted strategies. Hematology Am Soc Hematol Educ Program. 2023 12 08; 2023(1):164-170.
Score: 0.811
-
Disability-Free Survival: A Novel Morbidity Endpoint for Older Adult Allogeneic Hematopoietic Cell Transplantation. Transplant Cell Ther. 2026 Jul; 32(7):877.e1-877.e11.
Score: 0.238
-
Myelofibrosis-associated extramedullary hematopoiesis: Insights into hepatic, pulmonary, and thrombotic complications. Blood Rev. 2026 Jan; 75:101355.
Score: 0.233
-
Long-term survival outcomes of allo-HCT in AML with fludarabine/melphalan conditioning and tacrolimus/sirolimus GVHD prophylaxis. Bone Marrow Transplant. 2026 01; 61(1):82-91.
Score: 0.232
-
Outcomes after Melphalan-Based Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Renal Impairment. Transplant Cell Ther. 2025 Oct; 31(10):824.e1-824.e13.
Score: 0.226
-
Impact of hyperhydration on fluid overload and hematopoietic cell transplant after post-transplant cyclophosphamide-based graft-versus-host-disease prophylaxis. Front Immunol. 2025; 16:1543099.
Score: 0.220
-
Fludarabine melphalan reduced intensity conditioning vs radiation-based myeloablative conditioning in patients undergoing allogeneic transplantation for acute myeloid leukemia with measurable residual disease. Bone Marrow Transplant. 2025 02; 60(2):165-174.
Score: 0.218
-
Impact of spliceosome mutation on outcomes of myelodysplastic syndrome and chronic myelomonocytic leukemia patients undergoing allogeneic hematopoietic cell transplantation. Leuk Res. 2024 10; 145:107565.
Score: 0.213
-
Hypomethylating Agents are Effective in Treatment for Relapsed Myelofibrosis After Allogeneic Hematopoietic Cell Transplantation. Transplant Cell Ther. 2024 11; 30(11):1091.e1-1091.e8.
Score: 0.213
-
Comparing transplant outcomes in ALL patients after myeloablative conditioning in mismatch-related or unrelated donor settings. Bone Marrow Transplant. 2024 Nov; 59(11):1542-1551.
Score: 0.213
-
Total Body Irradiation and Fludarabine with Post-Transplantation Cyclophosphamide for Mismatched Related or Unrelated Donor Hematopoietic Cell Transplantation. Transplant Cell Ther. 2024 10; 30(10):1013.e1-1013.e12.
Score: 0.212
-
High remission rates and transition to allogeneic transplant in older patients with newly diagnosed FLT-3 mutated acute myelogenous leukemia with midostaurin plus intensive chemotherapy. Leuk Lymphoma. 2024 07; 65(7):1020-1023.
Score: 0.208
-
Tocilizumab for Cytokine Release Syndrome Management After Haploidentical Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis. Transplant Cell Ther. 2023 08; 29(8):515.e1-515.e7.
Score: 0.195
-
High response rates and transition to transplant after novel targeted and cellular therapies in adults with relapsed/refractory acute lymphoblastic leukemia with Philadelphia-like fusions. Am J Hematol. 2023 06; 98(6):848-856.
Score: 0.193
-
Functional SARS-CoV-2-specific T cells of donor origin in allogeneic stem cell transplant recipients of a T-cell-replete infusion: A prospective observational study. Front Immunol. 2023; 14:1114131.
Score: 0.192
-
Adoptive transfer of functional SARS-COV-2-specific immunity from donor graft to hematopoietic stem cell transplant recipients. Am J Hematol. 2022 11; 97(11):E404-E407.
Score: 0.186
-
Tacrolimus initial steady state level in post-transplant cyclophosphamide-based GvHD prophylaxis regimens. Bone Marrow Transplant. 2022 02; 57(2):232-242.
Score: 0.176
-
Characteristics and Trends of Adult Acute Lymphoblastic Leukemia in a Large, Public Safety-Net Hospital. Clin Lymphoma Myeloma Leuk. 2020 06; 20(6):e320-e327.
Score: 0.156
-
Role of ROCK2 inhibitors in the treatment of chronic graft-versus-host disease. Expert Opin Investig Drugs. 2025 May; 34(5):391-400.
Score: 0.056